Painreform Ltd (PRFX)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.78-7.64%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$7,000

Net profit

$-1.4M

Net margin

-19,978.6%

Market cap

$3.0M

Forward P/E

0.0

P/B

0.22

Book value

$5.22

EPS (TTM)

$-4.09

52-week high

$7.95

52-week low

$0.78

50-day MA

$0.97

200-day MA

$2.01

Beta

1.08

with an average price target of $12.00.

Insiders

6.58%

Institutions

6.69%

Fund	Stake
Yorkville Advisors Global, LP	2.32%
Jane Street Group LLC	2.30%
Citadel Advisors Llc	0.82%
UBS Group AG	0.30%
Morgan Stanley - Brokerage Accounts	0.08%
Royal Bank of Canada	0.01%
Advisor Group Holdings, Inc.	0.00%
Rockefeller Capital Management L.P.	0.00%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Painreform Ltd — free to start.

Data updated 2026-10-19.